Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Abseamed

Abseamed 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 2 000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Abseamed 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Abseamed 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Abseamed 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Abseamed 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Abseamed 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Abseamed 10 000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Abseamed 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17

HOS-117339 · Präparat HOS-094577

Paediatric population with chronic renal failure on haemodialysis The exposure of paediatric patients with chronic renal failure on haemodialysis in clinical studies and post-marketing experience is limited. No paediatric-specific adverse reactions not mentioned previously in the table above, or any that were not consistent with the underlying disease were reported in this population.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.